Terauchi, Y., Utsunomiya, K., Yasui, A., Seki, T., Cheng, G., Shiki, K. and Lee, J. (2019) Safety and Efficacy of Empagliflozin as Add-On Therapy to GLP-1 Receptor Agonist (Liraglutide) in Japanese Patients with Type 2 Diabetes Mellitus: A Randomised, Double-Blind, Parallel-Group Phase 4 Study. Diabetes Therapy, 10, 951-963.
https://doi.org/10.1007/s13300-019-0604-8

has been cited by the following article:

• TITLE: Overview of Type 2 Diabetes Drugs on the Market

  AUTHORS: Yuxi Hu, Yongshou Chen

  KEYWORDS: Type 2 Diabetes Mellitus, Insulin, Sodium-Dependent Glucose Transporters 2, Glucagon-Like Peptide-1

  JOURNAL NAME: Journal of Biosciences and Medicines, Vol.8 No.8, August 6, 2020

  ABSTRACT: Type 2 Diabetes Mellitus (T2DM) is a systemic metabolic disorder with complex pathogenesis. In recent years, a variety of new T2DM drugs have emerged, such as sodium-dependent glucose transporters 2 (SGLT-2) inhibitors, glucagon-like peptide-1 (GLP-1) receptor agonists and dipeptidyl peptidase-4 (DPP-4) inhibitors. As traditional medicines, insulin also has developed kinds of formulations such as quick-acting or premixed insulin. In addition, new treatment schedules combining multiple drugs are also fully explored. The efficacy, the administration, the mechanism, the safety and the price of these drugs are all different, providing patients with multiple options. This paper reviews the main types of type 2 diabetes drugs on the market and describes the mechanism of action. The representative type 2 diabetes treatment drugs are listed, and the advantages and disadvantages of these representative drugs are preliminarily evaluated. This information is reviewed to help doctors with clinical medication.